Zymeworks Inc (ZYME)

$26.31 +0.59 (2.29%)
Market Cap 1.92B
Revenue (ttm) 105.97M
Net Income (ttm) -81.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 23.38
Profit Margin -76.56%
Debt to Equity Ratio 0.00
Volume 563,700
Avg Vol 694,410
Day's Range N/A - N/A
Shares Out 73.02M
Stochastic %K 84%
Beta 1.13
Analysts Strong Sell
Price Target $39.69

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 4:35 PM
The XBI is up 25% over the last 15 days & is now trading at record highs (excluding that 11 day period in Feb 2021 when it traded over $160/share). There are now 6 commercial-stage oncology focused bios hanging around the $2B MC range. Here's how this peer group has traded over the last 15 days. $URGN has been the biggest winner up 36%. We suspect an exit is imminent. $IOVA $NUVB $ANAB $ZYME
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jul. 3 at 4:00 AM
$ZYME sheep farmer celebrating his call this week
0 · Reply
TopTierNewswire
TopTierNewswire Jun. 30 at 9:52 PM
$FCEL , $BB , $ZYME - top runners on the Top Tier Newswire AI model. Huge gains today!
0 · Reply
Boris_Badenov
Boris_Badenov Jun. 30 at 7:34 PM
$ZYME An interesting part of the Theravance deal is the $2.5 billion in Irish tax attributes. So, let's see, is there an Ireland based biotech company that could figure out a use for these? Oh, here's one, Jazz Pharma.
2 · Reply
NoBSPls
NoBSPls Jun. 30 at 6:30 PM
$ZYME Bought in Dec 2022. Average $6.70. The beauty of “Get it and Forget it”.
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:15 PM
$ZYME sorry that’s 12%
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:14 PM
$ZYME to buy here you need to understand what EcoR1 and zymeworks are building and why. Institutions are chasing the stock price. Up 11% on average volume.
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:12 PM
$ZYME who wants to buy at cash flow positiv biotech with predictable royalties and huge potential upside on oncology pipeline incl. ZW191 and a validated ADC platform. Almost like a bond with a mega million coupon 🤣. ExoR1 is dressing up Zyme for a sale.
0 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 30 at 6:00 PM
$ZYME $TBPH
1 · Reply
Nickhzap
Nickhzap Jun. 30 at 5:43 PM
$ZYME bahahahhahahahahahhaahhahahhahahahahahahahhahahahahah 🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡
0 · Reply
Latest News on ZYME
Zymeworks price target raised to $37 from $34 at Wells Fargo

2026-06-30T10:25:21.000Z - 4 days ago

Zymeworks price target raised to $37 from $34 at Wells Fargo

Zymeworks price target raised to $37 from $35 at Citi

2026-06-30T09:45:22.000Z - 4 days ago

Zymeworks price target raised to $37 from $35 at Citi

TBPH

Zymeworks Transcript: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 5 days ago

Zymeworks Transcript: M&A announcement

Zymeworks Press release: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 5 days ago

Zymeworks Press release: M&A announcement

Zymeworks Slides: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 5 days ago

Zymeworks Slides: M&A announcement

M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B

2026-06-29T10:33:25.000Z - 5 days ago

M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B

TBPH

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

2026-06-29T10:15:32.000Z - 5 days ago

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

TBPH

Zymeworks strikes $929 million deal for Theravance Biopharma

Jun 29, 2026, 6:13 AM EDT - 5 days ago

Zymeworks strikes $929 million deal for Theravance Biopharma

TBPH

Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M

2026-06-29T10:10:41.000Z - 5 days ago

Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M

TBPH

Zymeworks to acquire Theravance Biopharma for $17.00 per share

2026-06-29T10:06:12.000Z - 5 days ago

Zymeworks to acquire Theravance Biopharma for $17.00 per share

TBPH

Zymeworks to Acquire Theravance Biopharma, Inc.

Jun 29, 2026, 6:00 AM EDT - 5 days ago

Zymeworks to Acquire Theravance Biopharma, Inc.

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Jun 18, 2026, 8:00 AM EDT - 16 days ago

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Zymeworks presents new clinical data on Phase 1 study of ZW191

2026-06-14T23:15:05.000Z - 19 days ago

Zymeworks presents new clinical data on Phase 1 study of ZW191

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Jun 14, 2026, 6:05 PM EDT - 19 days ago

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks assumed with a Buy at Truist

2026-06-09T12:13:20.000Z - 25 days ago

Zymeworks assumed with a Buy at Truist

Zymeworks Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:45 AM EDT - 4 weeks ago

Zymeworks Transcript: Jefferies Global Healthcare Conference 2026

Zymeworks authorizes share repurchase program of up to $125M

2026-05-14T22:14:23.000Z - 7 weeks ago

Zymeworks authorizes share repurchase program of up to $125M

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026, 4:05 PM EDT - 7 weeks ago

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

May 13, 2026, 6:00 AM EDT - 7 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks reports Q1 EPS (59c), consensus (10c)

2026-05-07T21:19:18.000Z - 2 months ago

Zymeworks reports Q1 EPS (59c), consensus (10c)

Zymeworks Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Zymeworks Earnings Call Transcript: Q1 2026

Zymeworks Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Zymeworks Earnings release: Q1 2026

Zymeworks Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Zymeworks Slides: Q1 2026

Zymeworks Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Zymeworks Quarterly report: Q1 2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 2 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191

2026-04-21T21:35:17.000Z - 2 months ago

Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Apr 21, 2026, 5:30 PM EDT - 2 months ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 9:30 AM EDT - 2 months ago

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Apr 17, 2026, 3:00 PM EDT - 2 months ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Apr 16, 2026, 6:00 AM EDT - 2 months ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 10:15 AM EDT - 2 months ago

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Zymeworks appoints new Head of R&D and Chief Business Officer

2026-04-09T10:11:05.000Z - 3 months ago

Zymeworks appoints new Head of R&D and Chief Business Officer

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Apr 9, 2026, 6:00 AM EDT - 3 months ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Zymeworks appoints Kristin Stafford as CFO

2026-04-01T10:06:59.000Z - 3 months ago

Zymeworks appoints Kristin Stafford as CFO

NVCR

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Apr 1, 2026, 6:00 AM EDT - 3 months ago

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Zymeworks receives FDA Fast Track Designation for ZW191

2026-03-30T10:06:54.000Z - 3 months ago

Zymeworks receives FDA Fast Track Designation for ZW191

Zymeworks announces Fast Track designation for ZW191 by FDA

2026-03-30T10:05:07.000Z - 3 months ago

Zymeworks announces Fast Track designation for ZW191 by FDA

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Mar 30, 2026, 6:00 AM EDT - 3 months ago

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

2026-03-18T11:51:22.000Z - 3 months ago

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

JAZZ

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 18, 2026, 7:46 AM EDT - 3 months ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 3 months ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 4 months ago

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:00 PM EDT - 4 months ago

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 4 months ago

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Zymeworks Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Zymeworks Earnings Call Transcript: Q4 2025

Zymeworks Earnings release: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Zymeworks Earnings release: Q4 2025

Zymeworks Slides: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Zymeworks Slides: Q4 2025

Zymeworks Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Zymeworks Annual report: Q4 2025

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:01 AM EST - 4 months ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 6:00 AM EST - 4 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Slides: Corporate presentation

Feb 27, 2026, 7:00 AM EST - 4 months ago

Zymeworks Slides: Corporate presentation

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Feb 12, 2026, 6:00 AM EST - 5 months ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 6 months ago

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 6 months ago

Zymeworks Slides: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

Zymeworks Slides: Corporate presentation

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Jan 12, 2026, 6:00 AM EST - 6 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jan 11, 2026, 6:00 PM EST - 6 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Jan 6, 2026, 1:34 PM EST - 6 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 7 months ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:00 AM EST - 7 months ago

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Zymeworks Transcript: Investor Update

Nov 18, 2025, 8:30 AM EST - 8 months ago

Zymeworks Transcript: Investor Update

Zymeworks Press release: Investor Update

Nov 18, 2025, 8:30 AM EST - 8 months ago

Zymeworks Press release: Investor Update

Zymeworks Slides: Investor Update

Nov 18, 2025, 8:30 AM EST - 8 months ago

Zymeworks Slides: Investor Update

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 8 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 8 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 8 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 8 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Proxy statement: Proxy filing

Nov 10, 2025, 7:00 AM EST - 8 months ago

Zymeworks Proxy statement: Proxy filing

Zymeworks Proxy statement: Proxy filing

Nov 10, 2025, 7:00 AM EST - 8 months ago

Zymeworks Proxy statement: Proxy filing

Zymeworks Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Zymeworks Earnings Call Transcript: Q3 2025

Zymeworks Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Zymeworks Earnings release: Q3 2025

Zymeworks Slides: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Zymeworks Slides: Q3 2025

Zymeworks Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Zymeworks Quarterly report: Q3 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Transcript: Study Result

Oct 23, 2025, 3:30 PM EDT - 9 months ago

Zymeworks Transcript: Study Result

Zymeworks Press release: Study Result

Oct 23, 2025, 3:30 PM EDT - 9 months ago

Zymeworks Press release: Study Result

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 9 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks Slides: Corporate Presentation

Oct 22, 2025, 6:00 PM EDT - 9 months ago

Zymeworks Slides: Corporate Presentation

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 9 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 9 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 9 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 4:30 PM EDT - 10 months ago

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 10 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 10 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 11 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Zymeworks Earnings Call Transcript: Q2 2025

Zymeworks Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Zymeworks Quarterly report: Q2 2025

Zymeworks Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Zymeworks Earnings release: Q2 2025

Zymeworks Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Zymeworks Slides: Q2 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 1 year ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 1 year ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q1 2025

Zymeworks Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Quarterly report: Q1 2025

Zymeworks Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings release: Q1 2025

Zymeworks Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Slides: Q1 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Zymeworks Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings Call Transcript: Q4 2024

Zymeworks Annual report: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Annual report: Q4 2024

Zymeworks Earnings release: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings release: Q4 2024

Zymeworks Slides: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Slides: Q4 2024

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 20, 2025, 2:00 PM EST - 1 year ago

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 18, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Feb 13, 2025, 6:00 AM EST - 1 year ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 4:35 PM
The XBI is up 25% over the last 15 days & is now trading at record highs (excluding that 11 day period in Feb 2021 when it traded over $160/share). There are now 6 commercial-stage oncology focused bios hanging around the $2B MC range. Here's how this peer group has traded over the last 15 days. $URGN has been the biggest winner up 36%. We suspect an exit is imminent. $IOVA $NUVB $ANAB $ZYME
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jul. 3 at 4:00 AM
$ZYME sheep farmer celebrating his call this week
0 · Reply
TopTierNewswire
TopTierNewswire Jun. 30 at 9:52 PM
$FCEL , $BB , $ZYME - top runners on the Top Tier Newswire AI model. Huge gains today!
0 · Reply
Boris_Badenov
Boris_Badenov Jun. 30 at 7:34 PM
$ZYME An interesting part of the Theravance deal is the $2.5 billion in Irish tax attributes. So, let's see, is there an Ireland based biotech company that could figure out a use for these? Oh, here's one, Jazz Pharma.
2 · Reply
NoBSPls
NoBSPls Jun. 30 at 6:30 PM
$ZYME Bought in Dec 2022. Average $6.70. The beauty of “Get it and Forget it”.
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:15 PM
$ZYME sorry that’s 12%
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:14 PM
$ZYME to buy here you need to understand what EcoR1 and zymeworks are building and why. Institutions are chasing the stock price. Up 11% on average volume.
0 · Reply
mostbullish
mostbullish Jun. 30 at 6:12 PM
$ZYME who wants to buy at cash flow positiv biotech with predictable royalties and huge potential upside on oncology pipeline incl. ZW191 and a validated ADC platform. Almost like a bond with a mega million coupon 🤣. ExoR1 is dressing up Zyme for a sale.
0 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 30 at 6:00 PM
$ZYME $TBPH
1 · Reply
Nickhzap
Nickhzap Jun. 30 at 5:43 PM
$ZYME bahahahhahahahahahhaahhahahhahahahahahahahhahahahahah 🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡
0 · Reply
JFDI
JFDI Jun. 30 at 2:27 PM
yo b, what $ZYME is it ?
0 · Reply
NyseDayTrader
NyseDayTrader Jun. 30 at 2:04 PM
$ZYME 🤣
1 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 29 at 9:31 PM
$SPRO DO NOT SELL TO $ZYME $GSK please. Thank you
0 · Reply
buzzkiller
buzzkiller Jun. 29 at 8:31 PM
$ZYME thank you for the shares Sellers - I hope the cash exchange serves you well.
0 · Reply
Nickhzap
Nickhzap Jun. 29 at 4:08 PM
$TBPH $ZYME 😂😂😂🤡🤡🤡🤡
0 · Reply
BuyingSheep
BuyingSheep Jun. 29 at 1:45 PM
$ZYME sure, 😂 🤡
1 · Reply
BuyingSheep
BuyingSheep Jun. 29 at 1:44 PM
$ZYME you nailed it, MM 😂
1 · Reply
mikesterz7
mikesterz7 Jun. 29 at 1:42 PM
$TBPH $ZYME Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
0 · Reply
JFais
JFais Jun. 29 at 1:04 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH (zero premium, $XBI doesn't like such deals) The next great (& unsexy) royalty aggregator (diversifying revenues & racking up tax benefits)
1 · Reply
JFais
JFais Jun. 29 at 12:58 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 29 at 12:52 PM
$TBPH (-3.1% pre) Theravance Biopharma to Be Acquired by $ZYME Zymeworks for $17 Per Share Plus CVR https://ooc.bz/l/106467
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 29 at 12:44 PM
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders $TBPH $ZYME https://stocktwits.com/news/equity/markets/tbph-zyme-takeover-deal-929-million-ampreloxetine/cZ19JeQR7hM
0 · Reply